Glivec (imatinib mesylate) in systemic sclerosis, a pilot study.
Recruiting
- Conditions
- Systemic sclerosis, Glivec (imatinib mesylate)
- Registration Number
- NL-OMON23406
- Lead Sponsor
- Erasmus Medical Center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
1. Patients with systemic sclerosis (either diffuse or limited) refractory to standard therapy
2. Adequate end organ function, defined as:
Exclusion Criteria
1. Age < 18 years
2. Previous or current malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary efficacy variable:<br /><br>·Rodnan skin score<br><br>
- Secondary Outcome Measures
Name Time Method Secondary efficacy variable:<br /><br>·Disease severity score<br /><br>·Number of digital ulcers<br /><br>·Pulmonary function test (CO-diffusion)<br /><br>·Kidney function as measured by creatinin clearance<br /><br>